Outcome phenotype* ID for the outcomes obtained through the MR Base platform or name of the outcome in FinnGen Study or consortium Sample size or cases/controls First author and reference
Macronutrient/alcohol
Total sugar intake† ukb-b-17079; 100008: Output from GWAS pipeline using Phesant derived variables from UKBB (MRC-IEU) UKBB 64 979 Elsworth, 201811
Carbohydrate intake† ukb-b-7244; 100005: Output from GWAS pipeline using Phesant derived variables from UKBB (MRC-IEU) UKBB 64 979 Elsworth, 201811
Protein intake† ukb-b-12043; 100003: Output from GWAS pipeline using Phesant derived variables from UKBB (MRC-IEU) UKBB 64 979 Elsworth, 201811
Fat intake† ukb-b-12379: 100004: Output from GWAS pipeline using Phesant derived variables from UKBB (MRC-IEU) UKBB 64 979 Elsworth, 201811
Alcohol intake† ukb-b-5359; 100022: Output from GWAS pipeline using Phesant derived variables from UKBB (MRC-IEU) UKBB 64 979 Elsworth, 201811
Anthropometric trait
Body mass index NA GIANT+UKBB 708 052 Pulit, 201912
Waist circumference ukb-b-9405; 48: Output from GWAS pipeline using Phesant derived variables from UKBB (MRC-IEU) UKBB 462 166 Elsworth, 201811
Hip circumference ukb-b-15590; 49: Output from GWAS pipeline using Phesant derived variables from UKBiobank (MRC-IEU) UKBB 462 117 Elsworth, 201811
Waist-to-hip ratio NA GIANT+UKBB 619 363 Pulit, 201912
Body fat percentage ukb-b-8909; 23099: Output from GWAS pipeline using Phesant derived variables from UKBB (MRC-IEU) UKBB 454 633 Elsworth, 201811
Cardiometabolic trait
Fasting glucose ebi-a-GCST005186 MAGIC 58 074 Manning, 201213
Fasting insulin ebi-a-GCST005185 MAGIC 51 750 Manning, 201213
Triglycerides ieu-a-302 GLGC 177 861 Willer, 201314
LDL cholesterol ieu-a-300 GLGC 173 082 Willer, 201314
HDL cholesterol ieu-a-299 GLGC 187 167 Willer, 201314
Systolic blood pressure ukb-b-20175; 4080: Output from GWAS pipeline using Phesant derived variables from UKBB (MRC-IEU) UKBB 436 419 Elsworth, 201811
Diastolic blood pressure ukb-b-7992; 4079: Output from GWAS pipeline using Phesant derived variables from UKBB (MRC-IEU) UKBB 436 424 Elsworth, 201811
C-reactive protein level NA UKBB 343 524 Neale, 2018
Liver enzyme/metabolite
Alanine aminotransferase ukb-d-30620_irnt UKBB NA Neale, 201811
Alkaline phosphatase ukb-d-30610_irnt UKBB NA Neale, 201811
Aspartate aminotransferase ukb-d-30650_irnt UKBB NA Neale, 201811
Gamma glutamyltransferase ukb-d-30730_irnt UKBB NA Neale, 201811
Direct bilirubin ukb-d-30660_irnt UKBB NA Neale, 201811
Total bilirubin ukb-d-30840_irnt UKBB NA Neale, 201811
Cardiometabolic disease
Coronary artery disease ebi-a-GCST005195 CARDIoGRAMplusC4D and UKBB 122 773/424 528 van der Harst, 201715
Coronary artery disease I9_IHD FinnGen consortium 25 366/151 533 NA16
Heart failure NA HERMES (incl. UKBB) 41 734/930 298 Shah, 202017
Heart failure I9_HEARTFAIL FinnGen consortium 9576/159 286 NA16
Atrial fibrillation ebi-a-GCST006414 NA (incl. UKBB) 60 620/970 216 Nielsen, 201818
Atrial fibrillation I9_AF FinnGen consortium 17 325/97 214 NA16
Ischemic stroke NA MEGASTROKE 34 217/406 111 Malik, 201819
Ischemic stroke ukb-d-I9_STR_EXH UKBB 3314/357 880 Neale, 201811
Ischemic stroke I9_STR_EXH FinnGen consortium 8046/164 286 NA16
Venous thromboembolism ukb-d-I9_VTE UKBB 4620/356 574 Neale, 201711
Venous thromboembolism I9_VTE FinnGen consortium 6913/169 986 NA16
Type 2 diabetes NA DIAMANTE (incl. UKBB) 74 124/824 006 Mahajan, 201820
Type 2 diabetes E4_DM2_STRICT (exclude type 1 diabetes) FinnGen consortium 22 338/148 190 NA16
Other outcomes
Alzheimer’s disease NA Consortia‡ and UKBB 71 880/383 378§ Jansen, 201921
Parental lifespan NA LifeGene and UKBB 639 143 Timmers, 201922